Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Biosimilars
Efficacy and Safety Equivalence of MYL-1402O and Reference in First-Line Treatment of Patients with Stage IV Nonsquamous NSCLC
Read More
Biosimilars
Clinical Similarity of Bevacizumab Biosimilar MB02 to Reference Bevacizumab in Patients with Nonsquamous NSCLC
Read More
Biosimilars
Demonstration of Efficacy and Safety Equivalence Between Bevacizumab Biosimilar FKB238 and Bevacizumab Reference in Nonsquamous NSCLC
Read More
Biosimilars
Efficacy and Safety of ABP 798 versus Rituximab: Comparative Clinical Study in Patients with Non-Hodgkin Lymphoma
Read More
Biosimilars
Efficacy and Safety Results of Sandoz Rituximab Biosimilar for the Treatment of Diffuse Large B-Cell Lymphoma
Read More
Biosimilars
Biosimilar Pegfilgrastim-cbqv Demonstrates Similar Clinical Efficacy to the Pegfilgrastim Reference in a Real-World Setting
Read More
Biosimilars
Cost-Savings of Biosimilar Pegfilgrastim in a Medicare Oncology Care Model Population
Read More
Biosimilars
Phase 3 Study Comparing SB3 and Reference Trastuzumab in HER2-Positive, Early or Locally Advanced Breast Cancer in the Neoadjuvant Setting: 4-Year Follow-Up
Read More
Biosimilars
Cost-Savings from Conversion to Biosimilar Pegfilgrastim-cbqv Providing Expanded Access to Prophylaxis and Antineoplastic Therapy in NHL
Read More
Biosimilars
Real-World Utilization of Infliximab and Its Biosimilars in Rheumatoid Arthritis
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 30